Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors

Summary

This is a prospective, open label, single arm clinical trial to evaluate the safety and the preliminary efficacy of chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of advanced solid tumors positive for one of the following antigens: ephrin type-A receptor 2 (EphA2), claudin-18 isoform 2 (CLDN18.2) , trophoblast cell surface antigen 2 (Trop2), human epidermal growth factor receptor 2 (HER2), guanylyl cyclase-C (GCC), glypican-3 (GPC3) and carcinoembryonic antigen (CEA).

Timeline

Start

2026-06-10

Primary completion

2028-04-03

Completion

2028-04-03

Drugs

Indications